| ObjectiveTo observe the effect of Pingtiaoyin on 1-year survival rate, median survival time, AFP value, effect of TCM syndromes and quality of life of advanced PHC patients who belong to both qi and blood deficiency. To prolong the survival time in patients with advanced primary hepatocellular carcinoma, alleviating clinical symptoms, improving the quality of life,and providing new treatment methods.Methods64 PHC patients were all selected from our hospital from Dec.2013 to Feb.2015. They were randomly divided into two groups.Observation group (32 cases) used oral PingTiaoyin combing conventional symptomatic treatment; Control group (32 cases) used oral Hua Chan Su tablets combing conventional symptomatic treatment; then comparing the clinical efficacy of two groups.ResultsAfter treatment, the median survival time of the observation group was 397days; 1 year survival rate was 76.7%; in the control group, the median survival time was 324 days,1 year survival rate was 46.7%. After statistical analysis,1 year survival rate and the median survival time in the observation group were higher than in the control group (p< 0.05). The observation group and control groups’AFP values showed a declining trend, the difference is statistically significant (p< 0.01); in 4 and 6 months of treatment, observation groups’AFP value decreased significantly comparing with the control group, the difference is statistically significant (p< 0.01). Observation group and control group were able to reduce the TCM syndrome scores, in the treatment of 4 months and 6 months, the main symptoms scores of the observation group were significantly lower than them in the control group, the difference was statistically significant (p<0.05). The clinical study showed that the total improvement rate of traditional Chinese medicine in the observation group and the control group were 90.00% and 66.67% respectively, the improvement degree of the observation group was significantly higher than that of the control group, the difference was statistically significant (p<0.05). Observation group and control group were able to improve the FACT-Hep score, in the treatment of 2 months,4 months and 6 months,the score in the observation group was significantly higher than in the control group in different areas, the difference was statistically significant (p<0.05).Conclusions1.Pingtiaoyin can significantly improve the 1 year survival rate and the median survival time of advanced primary liver cancer patients;2.Pingtiaoyin significantly decreased the level of AFP value in advanced primary liver cancer patients;3.Pingtiaoyin can significantly decreased advanced primary liver cancer patients’TCM syndromes score;4.Pingtiaoyin can significantly improve the patients with primary liver cancer FACT-Hep score, improving the quality of life of patients. |
PDF Full Text Request